The trajectory of companies tied to the drug's past presents a challenging investment picture . While the initial surge generated substantial returns , generic alternatives have significantly eroded market share . Investing in related pharmaceutical firms now requires a discerning assessment of proprietary safeguards, evolving healthcare changes, a